2021
Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib
Holowka T, Cheung H, Malinis M, Gan G, Deng Y, Perreault S, Isufi I, Azar MM. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib. Journal Of Infection And Chemotherapy 2021, 27: 1700-1705. PMID: 34389223, DOI: 10.1016/j.jiac.2021.08.005.Peer-Reviewed Original ResearchConceptsInvasive fungal infectionsSerious infectionsRisk factorsHematologic malignanciesAdvanced ageMultivariate analysis risk factorsSmall molecule tyrosine kinase inhibitorsSingle tertiary care centerFungal infectionsConcurrent useCytotoxic agentsMolecule tyrosine kinase inhibitorsAnalysis risk factorsTertiary care centerTyrosine kinase inhibitorsElectronic medical recordsResult of infectionMost patientsClinical featuresInfected patientsMedical recordsCare centerImmune effectorsPatientsViral infection
2018
Central nervous system histoplasmosis
Wheat J, Myint T, Guo Y, Kemmer P, Hage C, Terry C, Azar MM, Riddell J, Ender P, Chen S, Shehab K, Cleveland K, Esguerra E, Johnson J, Wright P, Douglas V, Vergidis P, Ooi W, Baddley J, Bamberger D, Khairy R, Vikram H, Jenny-Avital E, Sivasubramanian G, Bowlware K, Pahud B, Sarria J, Tsai T, Assi M, Mocherla S, Prakash V, Allen D, Passaretti C, Huprikar S, Anderson A. Central nervous system histoplasmosis. Medicine 2018, 97: e0245. PMID: 29595679, PMCID: PMC5895412, DOI: 10.1097/md.0000000000010245.Peer-Reviewed Original ResearchConceptsCentral nervous system histoplasmosisPercent of patientsCerebrospinal fluidAmphotericin BCentral nervous system involvementSingle-center case seriesNervous system involvementLiposomal amphotericin BCenter case seriesOutcome of treatmentAnti-Histoplasma antibodiesRecognition of infectionPatients 54 yearsCNS histoplasmosisDeoxycholate formulationDisseminated histoplasmosisMost patientsAntigen testingAntibody testingCase seriesImmunodeficiency syndromeHistoplasma antigenHistoplasmosis infectionSystem involvementYear survival
2016
Histoplasmosis
Wheat LJ, Azar MM, Bahr NC, Spec A, Relich RF, Hage C. Histoplasmosis. Infectious Disease Clinics Of North America 2016, 30: 207-227. PMID: 26897068, DOI: 10.1016/j.idc.2015.10.009.Books
2015
Histoplasmosis: Up-to-Date Evidence-Based Approach to Diagnosis and Management
Hage CA, Azar MM, Bahr N, Loyd J, Wheat LJ. Histoplasmosis: Up-to-Date Evidence-Based Approach to Diagnosis and Management. Seminars In Respiratory And Critical Care Medicine 2015, 36: 729-745. PMID: 26398539, DOI: 10.1055/s-0035-1562899.BooksConceptsMost patientsPulmonary diseaseAcute pulmonary diseaseChronic cavitary pneumoniaCommon endemic mycosisProgressive disseminated diseaseCommon clinical presentationCommunity-acquired pneumoniaChronic pulmonary diseaseEvaluation of patientsLiposomal amphotericin BDate evidence-based approachGranulomatous inflammatory diseaseDiagnosis of histoplasmosisEvidence-based approachMediastinal manifestationsCavitary pneumoniaDisseminated diseaseClinical presentationCrohn's diseasePreferred agentClinical syndromeAnaerobic infectionsInflammatory diseasesEndemic mycosis